Navigation Links
Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
Date:6/21/2010

BEIJING, June 21 /PRNewswire/ -- OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.

In the investigator-initiated, single center, all-comers POTENT (Paclitaxel-eluting ballOon and bio-engineered progeniTor cEll-attracting stainless steel steNT in percutaneous treatment of coronary artery stenosis) registry, 32 percent of patients were diabetic, 86 percent were male, 58 percent had a previous myocardial infarction and the mean age of the study population was 56 years. Of the lesions treated, 46 percent were type B2/C lesions.  The patients received a pre-loading of dual antiplatelet therapy (DAPT) at least six hours prior to the percutaneous coronary intervention, and the DAPT was continued for three months. There were no in-hospital or 30 day major adverse cardiac events (MACE) reported.  There was one case of late stent thrombosis.

In the six-month clinical follow-up of the 50 patients in the study, the MACE rate was six percent, and the clinical driven target lesion revascularization (TLR) rate was four percent. In an optional nine-month angiographic follow-up of 35 patients, no patients exhibited binary restenosis. Alan Yean Yip Fong, M.D., of the Sarawak General Hospital in Malaysia presented the data during the World Congress of Cardiology Scientific Sessions 2010 in Beijing.

"We are very encouraged by the low MACE and binary restenosis rates, which are comparable to other stenting strategies and demo
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
5. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Ameritox, the nation,s leader in pain medication monitoring, ... become part of its Urine Drug Monitoring (UDM) ... improve the clinical outcomes for injured workers. ... in the workers, compensation industry, has used UDM ... strategy for several years. By establishing a comprehensive ...
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
(Date:5/23/2013)... 23, 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... of David A. Ramsay ... recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and his ... in our commercial group for the last four ...
Breaking Medicine Technology:Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
(Date:5/23/2013)... May 23, 2013 Dr. Damon Huffman of ... suffer from gum disease a revolutionary new treatment method with ... millions of Americans who suffer from periodontal disease, and many ... treatment. Dr. Huffman is hoping that LANAP will encourage ... treatment. , Periodontal disease can cause gums ...
(Date:5/23/2013)... Vinci surgical robot maker Intuitive Surgical defeated negligent training ... according to Bloomberg.* The Rottenstein Law Group LLP, which ... disappointment in the ruling but encourages those looking to ... verdict as representative of all da Vinci lawsuits. , ... Surgical Inc.; 09-2-03136-5, Superior Court, Port Orchard, Wash.) focused ...
(Date:5/23/2013)... Plano, TX (PRWEB) May 23, 2013 ... the Marketplace , Chaplains have been a part of ... this Memorial Day, like those preceding it, these men ... service to the United States of America. As ... trend of their migration to the workplace chaplaincy world. ...
(Date:5/23/2013)... May 23, 2013 Live ... contemporary services, provides the best business lead solution ... Its Call center Management solution features Free Web ... Call Limitation, Do-Not-Call Maintenance and "Automatic Transfer Retry". ... comprehensive campaign delivery and management system. , Its ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
Breaking Medicine News(10 mins):Health News:Humble, TX Dentist, Dr. Damon Huffman Now Offers Laser Periodontal Disease Treatment to Gum Disease Patients 2Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
... The Children,s Hospital of Philadelphia contributed important expertise to ... brain tumor typically found in children. The large multicenter ... holds intriguing clues to gene changes on signaling pathways ... The most common cancerous brain tumor in children, medulloblastoma ...
... , Orange, Calif., Dec.16, 2010 The American Heart Association ... of care for heart failure patients. The Get With ... UC Irvine Medical Center has achieved at least 85 percent ... heart failure patients. The medical center,s compliance rate was ...
... By Dennis Thompson HealthDay Reporter , THURSDAY, ... supplements for centuries to cure all manner of ills and ... the use of such plants as St. John,s wort and ... unknown. But the federal government is spending millions of ...
... a new report that bucks the concerns raised by the ... Health (BUSPH) (sph.bu.edu) researcher concludes that electronic cigarettes are much ... against tobacco-related diseases and death. The review, which ... the Journal of Public Health Policy , is the ...
... treatment of chronic pain from the patient,s perspective, there has ... pain. In a study in the November ... from the Regenstrief Institute, the Indiana University School of Medicine, ... Medical Center report that chronic pain takes a toll on ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... advisers urged the agency to take a new look at ... that include mercury. The FDA had ruled in 2009 ... "We need to see where the science is and ...
Cached Medicine News:Health News:CHOP experts collaborate in gene survey of childhood brain cancer; intriguing clues found 2Health News:UC Irvine Medical Center recognized for heart failure program 2Health News:U.S. Spending Millions to See if Herbs Truly Work 2Health News:U.S. Spending Millions to See if Herbs Truly Work 3Health News:Evidence suggests e-cigs safer than cigarettes, researcher claims 2Health News:It's a pain to take care of pain 2Health News:It's a pain to take care of pain 3Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 2Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 3
... Varicella-Zoster (VZ) test system ... and semi-quantitative detection of VZ ... by the indirect fluorescent antibody ... determine or confirm a recent ...
... Biotech Captia™ Varicella-Zoster Virus (VZV) ... is intended for the detection ... virus in human serum as ... of primary infection or reactivation. ...
... Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked Immunosorbent ... and quantitative determination of IgG antibody to ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
ELISA kit for Varicella-zoster IgM....
Medicine Products: